SCHEMBL268481

SCHEMBL268481

COCCC(C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669753 1.00
SCHEMBL12501794 1.00
Hydrochloric Acid SCHEMBL9109908 0.97
Hydrochloric Acid SCHEMBL5206725 0.97
SCHEMBL26647573 0.84 CA2 (0.36)
SCHEMBL5271914 0.82
SCHEMBL7947743 0.78 OPRM1 (0.50)
SCHEMBL6734023 0.78 OPRM1 (0.41)
SCHEMBL18829419 0.78
SCHEMBL4830064 0.78 PIK3CD (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3394017-A1 METHOD FOR PREPARING 2,3,3,3-TETRAFLUORO-1-PROPENE AND RECYCLING 2-CHLORO-3,3,3-TRIFLUOROPROPENE FREE OF IMPURITIES Arkema France (FR) 2018-10-31 EP claimed
WO-2017108518-A1 METHOD FOR PREPARING 2,3,3,3-TETRAFLUORO-1-PROPENE AND RECYCLING 2-CHLORO-3,3,3-TRIFLUOROPROPENE FREE OF IMPURITIES ARKEMA FRANCE (FR) 2017-06-29 WO claimed
EP-2592070-B1 Tetrazole-substituted arylamides HOFFMANN LA ROCHE (CH) 2016-08-31 EP claimed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO claimed
EP-2099757-A2 SULFOXIMINES AS KINASE INHIBITORS Allergan, Inc. (US) 2009-09-16 EP claimed
WO-2008061236-A2 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2008-05-22 WO claimed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 EP claimed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 WO claimed
US-12398097-B2 WDR5-MYC inhibitors VANDERBILT UNIVERSITY (US) 2025-08-26 US disclosed
EP-4583870-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER Mito Biopharma, LLC (US) 2025-07-16 EP disclosed
US-20250161281-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-22 US disclosed
US-20240405281-A1 Rechargeable Divalent Metal Batteries Having Fast Interfacial Charge Transfer Kinetics UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2024-12-05 US disclosed
US-20240279241-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS REDX PHARMA PLC (GB) 2024-08-22 US disclosed
WO-2024054766-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER MITO BIOPHARMA, LLC (US) 2024-03-14 WO disclosed
EP-0254183-A2 2,4-Diaminopyrimidines BAYER AG (DE) 1988-01-27 EP disclosed
EP-0230244-A2 2,4-Diamino-6-halogenoalkyl pyrimidines BAYER AG (DE) 1987-07-29 EP disclosed
US-4627872-A HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1986-12-09 US disclosed
EP-0184752-A2 2,4-Diaminopyrimidines BAYER AG (DE) 1986-06-18 EP disclosed
EP-0010256-B1 PROCESS FOR PREPARING SYMMETRIC 1,3-DISUBSTITUTED UREAS BASF Aktiengesellschaft (DE) 1982-12-29 EP disclosed
EP-0010256-A2 Process for preparing symmetric 1,3-disubstituted ureas BASF Aktiengesellschaft (DE) 1980-04-30 EP disclosed